AZTA — Azenta, Inc.

AZTA Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $159 million, up 6% year-over-year (4% organic growth).
• Full-Year Revenue: $594 million, up 4% (3% organic growth).
• Non-GAAP EPS: $0.21 for Q4 and $0.51 for the full year.
• Adjusted EBITDA Margin: 13% in Q4 (up 230 basis points) and 11.2% for the full year (up 310 basis points).
• Free Cash Flow: Usage of $6 million in Q4, with a full-year generation of $38 million, an improvement of $26 million year-over-year.
• Cash Position: $546 million in cash and marketable securities, with no debt.

2. Strategic Updates and Business Highlights

• Operational Improvements: Implementation of the Azenta Business System (ABS) has led to enhanced productivity, quality, and accountability.
• Cultural Shift: Focus on operational excellence embedded in daily routines, fostering employee-driven improvements.
• Commercial Restructuring: New leadership and expanded field presence aimed at accelerating growth.
• Growth Areas: Multiomics segment achieved record revenue of $73 million in Q4, driven by next-generation sequencing (NGS) and strong international performance.
• Investment Focus: Plans to reinvest savings into innovation, sales, marketing, and product management, alongside share repurchases and targeted M&A.

3. Forward Guidance and Outlook

• Fiscal 2026 Revenue Growth: Expected organic growth of 3% to 5%, with core revenue anticipated to decline 1% to 2% in Q1 due to macroeconomic factors.
• Profitability Goals: Targeting 300 basis points of adjusted EBITDA margin expansion and over 30% improvement in free cash flow year-over-year.
• Investor Day: Scheduled for December to outline long-term growth strategies and capital allocation priorities.

4. Challenges and Points of Concern

• Macroeconomic Headwinds: Ongoing uncertainty affecting capital expenditures, particularly in the U.S., impacting bookings and growth.
• Government Funding Issues: The recent government shutdown has delayed new grant approvals, affecting customer budgets and spending.
• Segment Performance Variability: While Multiomics showed strength, the Sample Management Solutions (SMS) segment faced softness in cryogenic stores and delayed capital spending decisions.
• Sanger Sequencing Decline: Continued low double-digit decline in Sanger sequencing revenue, although offset by growth in other areas.

5. Notable Q&A Insights

• Market Growth Expectations: Management believes the overall market is growing at 1% to 2%, with Azenta positioned to outgrow this due to its differentiated offerings.
• Segment-Specific Insights: SMS growth is expected to be mid-single digits, supported by a strong backlog and new commercial investments.
• M&A Strategy: Focus on tuck-in acquisitions to expand core businesses in Sample Management Solutions and automated solutions, with an emphasis on execution in 2026.
• Customer Insights: Management is actively engaging with customers to gauge market conditions and adapt strategies accordingly, particularly in response to government funding dynamics.

Overall, Azenta demonstrated resilience in a challenging environment, with a strong financial position and strategic initiatives aimed at driving future growth despite macroeconomic uncertainties.